Patents by Inventor Robert Hamatake

Robert Hamatake has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140249143
    Abstract: Provided are certain compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections.
    Type: Application
    Filed: October 19, 2012
    Publication date: September 4, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: Anna Lindsey Banka, Janos Botyanszki, Eric Gregory Burroughs, John George Catalano, Wendy Huang Chern, Hamilton D. Dickson, Margaret J. Gartland, Robert Hamatake, Hans Hofland, Jesse Daniel Keicher, Christopher Brooks Moore, John Bradford Shotwell, Matthew David Tallant, Jean-Philippe Therrien, Shihyun You
  • Publication number: 20080249131
    Abstract: Various carbonyl amides are employed in vitro and in vivo as non-nucleoside inhibitors of a reverse transcriptase, and particularly of HIV reverse transcriptase. Therefore, contemplated compounds may be employed in the treatment of HIV infected patients. Further contemplated aspects include pharmaceutical compositions comprising therapeutically effective amounts of contemplated compounds.
    Type: Application
    Filed: May 2, 2008
    Publication date: October 9, 2008
    Applicant: Ardea Biosciences, Inc.
    Inventors: Jean-Luc Girardet, Zhijun Zhang, Robert Hamatake, Martha A. De La Rosa, Esmir Gunic, Zhi Hong, Hong Woo Kim, Yung-hyo Koh, Shahul Nilar, Stephanie Shaw, Nanhua Yao
  • Publication number: 20060135556
    Abstract: Various carbonyl amides are employed in vitro and in vivo as non-nucleoside inhibitors of a reverse transcriptase, and particularly of HIV reverse transcriptase. Therefore, contemplated compounds may be employed in the treatment of HIV infected patients. Further contemplated aspects include pharmaceutical compositions comprising therapeutically effective amounts of contemplated compounds.
    Type: Application
    Filed: August 22, 2003
    Publication date: June 22, 2006
    Inventors: Jean-Luc Girardet, Zhijun Zhang, Robert Hamatake, Martha de la Rosa, Esmir Gunic, Zhi Hong, Hong Kim, Yung-Hyo Koh, Shahul Nilar, Stephanie Shaw, Nanhua Yao
  • Patent number: 6518014
    Abstract: Provided in one embodiment is a non-infectious, recombinant hepadnavirus core particle composition comprising isolated hepadnavirus core particles, template RNA encapsidated in the same core particles and hepadnavirus polymerase encapsidated in the same core particles, wherein, upon addition of deoxynucleoside triphosphates to the composition, the hepadnavirus polymerase incorporates deoxynucleotides from the added deoxynucleosides into reverse transcripts of the template RNA beginning with the first deoxynucleotide of the reverse transcript or within about 10 deoxynucleotides of the first deoxynucleotide of the reverse transcript. Another embodiment provides hapadnaviral core particles with all three functional components: (1) P; (2) C; and (3) a nucleic acid that serves as a template.
    Type: Grant
    Filed: July 11, 1997
    Date of Patent: February 11, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Maria Seifer, Robert Hamatake, David N. Standring